- Home
- AUPH vs SPRY Comparison
AUPH vs SPRY Comparison
Compare AUPH & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- SPRY
- Stock Information
- Founded
- AUPH 1993
- SPRY 2015
- Country
- AUPH Canada
- SPRY United States
- Employees
- AUPH N/A
- SPRY N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- SPRY Health Care
- Exchange
- AUPH Nasdaq
- SPRY Nasdaq
- Market Cap
- AUPH 1.1B
- SPRY 1.1B
- IPO Year
- AUPH 1999
- SPRY N/A
- Fundamental
- Price
- AUPH $8.13
- SPRY $12.17
- Analyst Decision
- AUPH Strong Buy
- SPRY Strong Buy
- Analyst Count
- AUPH 2
- SPRY 5
- Target Price
- AUPH $11.50
- SPRY $26.80
- AVG Volume (30 Days)
- AUPH 1.7M
- SPRY 1.3M
- Earning Date
- AUPH 05-01-2025
- SPRY 03-20-2025
- Dividend Yield
- AUPH N/A
- SPRY N/A
- EPS Growth
- AUPH N/A
- SPRY N/A
- EPS
- AUPH 0.04
- SPRY N/A
- Revenue
- AUPH $235,133,000.00
- SPRY $2,568,000.00
- Revenue This Year
- AUPH $13.80
- SPRY $61,233.33
- Revenue Next Year
- AUPH $24.57
- SPRY $585.54
- P/E Ratio
- AUPH $203.13
- SPRY N/A
- Revenue Growth
- AUPH 33.97
- SPRY 8460.00
- 52 Week Low
- AUPH $4.71
- SPRY $7.55
- 52 Week High
- AUPH $10.67
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- AUPH 51.32
- SPRY 60.53
- Support Level
- AUPH $7.92
- SPRY $10.00
- Resistance Level
- AUPH $8.85
- SPRY $11.55
- Average True Range (ATR)
- AUPH 0.42
- SPRY 0.72
- MACD
- AUPH 0.04
- SPRY 0.18
- Stochastic Oscillator
- AUPH 69.72
- SPRY 98.30
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.